Esketamine combined with dexmedetomidine
Phase 3Small molecule
Esketamine combined with dexmedetomidine is one of 23 small molecule programs targeting Sedation. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Analgesia
#DrugCompanyPhaseTrials
1Sufenta
LLeaf Vertical Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Penthrane
PPurdue Pharma, Canada
Phase 3
Oxycontin
PPurdue Pharma LP
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Intrathecal Morphine
Pacira Pharmaceuticals, IncPhase 3
Bupivacaine Liposome
Pacira Pharmaceuticals, IncPhase 3
Esketamine combined with dexmedetomidine
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Marcaine
IInnocoll
Phase 1
Narcan
SScienture
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postoperative Sleep Quality1 trial
Sedation1 trial
Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05466708·100 enrolled
Chronic Pain, Postoperative1 trial
Analgesia1 trial
Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (ESSENTIAL Trial): Study Protocol of a Randomized Controlled Trial
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Approved·NCT07377981·356 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details